ALDX logo

ALDEYRA THERAPEUTICS INC

ALDXNASDAQ
🏆 #4392 by market capEarnings Nov 2US Equity
$0.69▲ $0.01 (+0.83%)
Latest quote
🔔
Track ALDX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.8%
7d▲ 7.9%
14d▼ 6.5%
30d▼ 47.6%
ytd▼ 86.6%
1y▼ 86.3%
🏦Market Cap
$42M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.69 – $0.69
52-Week Range
$0.60 – $5.93
Volume (shares)
200
Avg Volume (shares)
—
Shares Outstanding
60.3M
Next Earnings
2026-11-02

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-0.38
Dividend Yield
—
Dilution (1yr)
+1.1%
ALDX logo

ALDEYRA THERAPEUTICS INC

ALDX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$35M▼ −41.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$33M▼ −22.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
60.2M▲ +1.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$55M▲ +$15M YoY
StockOtter · stockotter.space

About ALDEYRA THERAPEUTICS INC

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
11 analysts
Strong Buy4
Buy5
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.